THE DEAL, AT A GLANCE
From the announcementIambic Therapeutics
01Who is involvedBacked by ARCH, VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedIambic Therapeutics raised $100M Series AFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersIambic Therapeutics is using Series A capital to move IAM1363, an AI-designed drug, into Phase 1 clinical trials while positioning predictive ADMET optimization as a way…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Iambic Therapeutics · Financing Record
Explore source-linked visual explanations for Iambic Therapeutics. Unsupported claims are withheld while source review continues.
Record 1215 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →